Ibogaine for Opioid Addiction — What the Evidence Shows

Not completely, and the honest framing matters. In the largest published series mean withdrawal scores fell from 31 to 14 within about three days (Brown & Alper 2017, n=30, open-label) — a large reduction, not the total elimination sometimes claimed. The severe physical agony of withdrawal (muscle cramps, vomiting, sweating, insomnia) is replaced by fatigue during the recovery phase.

Yes, but requires a physician-guided tapering protocol. Suboxone must be fully cleared before ibogaine can work on opioid receptors (typically 2–4 weeks of taper). Methadone requires a longer transition due to its long half-life. Never stop these medications abruptly.

There is no reliable one-year sobriety figure for ibogaine — the published follow-up literature is two small open-label studies without control groups. The neuroplasticity window lasts 4–12 weeks — what you build during that window largely determines long-term outcomes.

Ibogaine is Schedule I in the US. Treatment is conducted at licensed clinics in Mexico, Portugal, the Netherlands, Costa Rica, and South Africa. There is no US law prohibiting Americans from traveling abroad for treatment. The FDA has granted ibogaine Breakthrough Therapy status and clinical trials are active.

Yes, and any provider who avoids this question should be avoided. In the New Zealand twelve-month follow-up study, one of the fourteen enrolled participants died during treatment (Noller et al., 2018). Ibogaine can prolong the Q–T interval, and the serious cases concentrate in people with a pre-existing heart condition who were not properly screened — which is exactly what screening is for. That is why an ECG, a full medication review and continuous cardiac monitoring are standard in a real program, and why opioid cases specifically require coming off long-acting opioids first.

That is not a comparison the evidence can currently support, and we will not pretend otherwise. Methadone and buprenorphine are FDA-approved, have been tested in randomised controlled trials and carry decades of outcome data. Ibogaine has two small observational studies for opioid use disorder and no completed randomised controlled trial. What ibogaine offers that maintenance treatment does not is a single-session approach rather than an ongoing prescription. What maintenance offers is a far larger and more reliable evidence base.